

## **Mechanism of Action of Emergency Contraceptive Pills**

ECPs do not cause abortion<sup>1</sup> or harm an established pregnancy. Pregnancy begins with implantation according to medical authorities such as the US FDA, the National Institutes of Health<sup>2</sup> and ACOG.<sup>3</sup>

### **Ulipristal Acetate (UPA)**

One study has demonstrated that UPA can delay ovulation.<sup>4</sup> In this study, 34 women were treated when the size of the leading follicle was at least 18 mm. Each woman contributed one cycle treated with placebo and another with UPA. Follicular rupture failed to occur within 5 days following UPA treatment in 20 (59%) subjects while normal ovulation was observed in all women within 5 days after placebo intake. Follicular rupture failed to occur within 5 days after treatment with UPA in all women treated before onset of the LH surge, in 79% of women treated after the onset of the LH surge but before the LH peak, and in 8% of women treated after the LH peak. Another study found that UPA altered the endometrium, but whether this change would inhibit implantation is unknown.<sup>5</sup>

### **Progestin-only Emergency Contraceptive Pills**

Early treatment with ECPs containing only the progestin levonorgestrel has been shown to impair the ovulatory process and luteal function.<sup>6,7,8,9,10</sup> No effect on the endometrium was found in two studies,<sup>7,8</sup> but in another study levonorgestrel taken before the LH surge altered the luteal phase secretory pattern of glycodelin in serum and the endometrium.<sup>11</sup> However, this finding was not confirmed in two later studies explicitly designed to assess endometrial glycodelin expression.<sup>12,13</sup> The second of these studies also found no effect on other endometrial receptivity biomarkers or progesterone receptors. Levonorgestrel does not impair the attachment of human embryos to in vitro endometrial constructs and has no effect on the expression of endometrial receptivity markers.<sup>14,15</sup> In a study conducted more than 30 years ago, levonorgestrel was found to interfere with sperm migration and function at all levels of the genital tract;<sup>16</sup> however, another study designed to assess this issue found that 1500 mcg levonorgestrel had no effect on the quality of cervical mucus or on the penetration of spermatozoa in the uterine cavity,<sup>12</sup> and a recent study found an effect on sperm function only with much higher levels of levonorgestrel than are used for emergency contraception.<sup>17</sup>

The reduced efficacy with a delay in treatment, even when use is adjusted for cycle day of unprotected intercourse,<sup>18</sup> suggests that interference with implantation is likely not an important effect of ECPs. If ECPs did prevent all implantations, then delays in use should not reduce their efficacy as long as they are used before implantation.<sup>19</sup> Results of a simulation model demonstrated that the levonorgestrel regimen could not be effective on average when started after 96 hours without a post-fertilization effect, because with increasing delay, a greater proportion of women would be too near to ovulation.<sup>20</sup>

Studies in the rat and the Cebus monkey demonstrate that levonorgestrel administered in doses that inhibit ovulation has no post-fertilization effect that impairs fertility.<sup>21,22,23</sup> However, the extent to which these results can be extrapolated to women is unknown.

Croxatto and colleagues have argued that most, if not all, of the contraceptive effect of levonorgestrel only ECPs can be explained by inhibited or dysfunctional ovulation, based on the existing animal and human studies, including two human studies comparing observed and expected pregnancies when levonorgestrel-only ECPs were administered before and after

ovulation. In the first study, no pregnancies were observed when levonorgestrel-only ECPs were taken before the day of ovulation (in contrast to the 4 pregnancies that would have been expected without use of ECPs), whereas 3 pregnancies occurred when ECPs were taken after the day of ovulation (versus 3.5 expected pregnancies).<sup>24</sup> In a follow-up study no pregnancies were observed when levonorgestrel-only ECPs were taken before the day of ovulation (in contrast to the 13 pregnancies that would have been expected without use of ECPs, whereas when ECPs were taken on or after the day of ovulation, 6 pregnancies occurred (*versus* 7 expected pregnancies).<sup>25</sup> While some find the existing human and animal studies adequate to conclude that levonorgestrel ECPs have no post-fertilization effect,<sup>26</sup> others may always feel that this question has not been unequivocally answered. The best available evidence indicates that levonorgestrel ECPs prevent pregnancy by mechanisms that do not involve interference with post-fertilization events.<sup>19</sup>

### **Combined Emergency Contraceptive Pills**

Several clinical studies have shown that combined ECPs containing the estrogen ethinyl estradiol and the progestin levonorgestrel can inhibit or delay ovulation.<sup>27,28,29,30</sup> This mechanism of action may explain the effectiveness of combined ECPs when used during the first half of the menstrual cycle, before ovulation has occurred. Some studies have shown histologic or biochemical alterations in the endometrium after treatment with the regimen, leading to the conclusion that combined ECPs may act by impairing endometrial receptivity to subsequent implantation of a fertilized egg.<sup>28,31,32,33</sup> However, other more recent studies have found no such effects on the endometrium.<sup>27,34,35</sup> Additional possible mechanisms include interference with corpus luteum function; thickening of the cervical mucus resulting in trapping of sperm; alterations in the tubal transport of sperm, egg, or embryo; and direct inhibition of fertilization.<sup>21,36,37,38</sup> No clinical data exist regarding the last three of these possibilities. Nevertheless, statistical evidence on the effectiveness of combined ECPs suggests that if the regimen is as effective as was initially claimed, it must have a mechanism of action other than delaying or preventing ovulation.<sup>39</sup> However, as it now appears that the effectiveness of combined ECPs was initially overestimated, there is less concern that ECPs do more than delay or prevent ovulation.<sup>40</sup> Nevertheless, the important point is that effectiveness and mechanism of action are not independent.<sup>20</sup> For example, a regimen without a post-fertilization effect could not be 100% effective in typical populations, which inevitably include some women who take ECPs after fertilization has already occurred.

To make an informed choice, women must know that ECPs—like all regular hormonal contraceptives such as the birth control pill, the implant Implanon, the vaginal ring NuvaRing, the Evra patch, and the injectable Depo-Provera,<sup>41</sup> and even breastfeeding<sup>42,43,44,45</sup>—prevent pregnancy primarily by delaying or inhibiting ovulation and inhibiting fertilization, but may at times inhibit implantation of a fertilized egg in the endometrium. At the same time, however, all women should be informed that the best available evidence is consistent with the hypothesis that levonorgestrel and ulipristal acetate ECPs' ability to prevent pregnancy can be fully accounted for by mechanisms that do not involve interference with post-fertilization events. That is the information we provide on the Emergency Contraception Website ([not-2-late.com](http://not-2-late.com)) and the Emergency Contraception Hotline (1-888-NOT-2-LATE).

James Trussell, PhD

Director  
Office of Population Research  
Princeton University  
Princeton NJ 08544

May 18, 2010

## References

1. Levonorgestrel for emergency contraception. [fact sheet]. Geneva (Switzerland) World Health Organization; 2005 March.
2. Protection of Human Subjects, 45 C.F.R. Sect. 46.202 (2009).
3. Hughes EC (ed). Committee on Terminology, The American College of Obstetricians and Gynecologists, Obstetric-Gynecologic Terminology. Philadelphia (PA): F.A. Davis Company; 1972.
4. Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E, Croxatto HB. Immediate preovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. *Hum Reprod*. Forthcoming 2010.
5. Stratton P, Levens ED, Hartog B, Piquion J, Wei Q, Merino M, Nieman LK. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. *Fertil Steril*. 2010;93:2035-41.
6. Hapangama D, Glasier AF, Baird DT. The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. *Contraception*. 2001;63:123-9.
7. Durand M, del Carmen Cravioto M, Raymond EG, Durán-Sánchez O, De la Luz Cruz-Hinojosa L, Castell-Rodríguez A, Schiavon R, Larrea F. On the mechanisms of action of short-term levonorgestrel administration in emergency contraception. *Contraception*. 2001;64:227-34.
8. Marions L, Hultenby K, Lindell I, Sun X, Ståbi B, Gemzell Danielsson K. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. *Obstet Gynecol*. 2002;100:65-71.
9. Marions L, Cekan SZ, Bygdeman M, Gemzell-Danielsson K. Effect of emergency contraception with levonorgestrel or mifepristone on ovarian function. *Contraception*. 2004;69:373-7.
10. Croxatto HB, Brache V, Pavez M, Cochon L, Forcelledo ML, Alvarez F, Massai R, Faundes A, Salvatierra AM. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. *Contraception*. 2004;70:442-50.
11. Durand M, Séppala M, del Carmen Cravioto M, Koistinen H, Koistinen R, González-Macedo J, Larrea F. Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodeclin in serum and endometrium during the luteal phase of the menstrual cycle. *Contraception*. 2005;71:451-7.

12. do Nascimento JA, Seppala M, Perdigo A, Espejo-Arce X, Munuce MJ, Hautala L, Koistinen R, Andrade L, Bahamondes L. In vivo assessment of the human sperm acrosome reaction and the expression of glycodelin-A in human endometrium after levonorgestrel-emergency contraceptive pill administration. *Hum Reprod.* 2007;22:2190-5.
13. Palomino WA, Kohen P, Devoto L. A single midcycle dose of levonorgestrel similar to emergency contraceptive does not alter the expression of the L-selectin ligand or molecular markers of endometrial receptivity. *Fertil Steril.* Forthcoming 2009.
14. Lalitkumar PG, Lalitkumar S, Meng CX, Stavreus-Evers A, Hambiliki F, Bentin-Ley U, Gemzell-Danielsson K. Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model. *Human Reprod.* 2007;22:3031-7.
15. Meng CX, Andersson KL, Bentin-Ley U, Gemzell-Danielsson K, Lalitkumar PG. Effect of levonorgestrel and mifepristone on endometrial receptivity markers in a three-dimensional human endometrial cell culture model. *Fertil Steril.* 2009;91:256-64.
16. Kesserü E, Garmendia F, Westphal N, Parada J. The hormonal and peripheral effects of d-norgestrel in postcoital contraception. *Contraception.* 1974;10:411-24.
17. Yeung WS, Chiu PC, Wang CH, Yao YQ, Ho PC. The effects of levonorgestrel on various sperm functions. *Contraception.* 2002;66:453-7.
18. Piaggio G, von Hertzen H, Grimes DA, Van Look PFA. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. *Lancet.* 1999;353:721.
19. Davidoff F, Trussell J. Plan B and the politics of doubt. *JAMA.* 2006;296:1775-8.
20. Mikolajczyk RT, Stanford JB. Levonorgestrel emergency contraception: a joint analysis of effectiveness and mechanism of action. *Fertil Steril.* 2007;88:565-71.
21. Croxatto HB, Devoto L, Durand M, Ezcurra E, Larrea F, Nagle C, Ortiz ME, Vantman D, Vega M, von Hertzen H. Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. *Contraception.* 2001;63:111-21.
22. Müller AL, Lladós CM, Croxatto HB. Postcoital treatment with levonorgestrel does not disrupt postfertilization events in the rat. *Contraception.* 2003;67:415-19.
23. Ortiz ME, Ortiz RE, Fuentes MA, Parraguez VH, Croxatto HB. Postcoital administration of levonorgestrel does not interfere with post-fertilization events in the new-world monkey *Cebus apella*. *Hum Reprod.* 2004;19:1352-6.
24. Novikova N, Weisberg E, Stanczyk FZ, Croxatto HB, Fraser, IS. Effectiveness of levonorgestrel emergency contraception given before or after ovulation—a pilot study. *Contraception.* 2006;74:349-50.
25. Noé G, Croxatto HB, Salvatierra AM, Reyes V, Villarroel C, Muñoz C, Morales G, Retamales A. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. *Contraception.* 2010;81:414-20.
26. Emergency contraception's mode of action clarified. *Popul Briefs.* 2005;11:3. [cited 2006 Mar 23]. Available from: <http://www.popcouncil.org/pdfs/popbriefs/pbmay05.pdf>

27. Swahn ML, Westlund P, Johannisson E, Bygdeman M. Effect of post-coital contraceptive methods on the endometrium and the menstrual cycle. *Acta Obstet Gynecol Scand.* 1996;75:738-44.
28. Ling WY, Robichaud A, Zayid I, Wrixon W, MacLeod SC. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. *Fertil Steril.* 1979;32:297-302.
29. Rowlands S, Kubba AA, Guillebaud J, Bounds W. A possible mechanism of action of danazol and an ethinylestradiol/norgestrel combination used as postcoital contraceptive agents. *Contraception.* 1986;33:539-45.
30. Croxatto HB, Fuentalba B, Brache V, Salvatierra AM, Alvarez F, Massai R, Cochon L, Faundes A. Effects of the Yuzpe regimen, given during the follicular phase, on ovarian function. *Contraception.* 2002;65:121-8.
31. Kubba AA, White JO, Guillebaud J, Elder MG. The biochemistry of human endometrium after two regimens of postcoital contraception: a dl-norgestrel/ethinylestradiol combination or danazol. *Fertil Steril.* 1986;45:512-16.
32. Ling WY, Wrixon W, Zayid I, Acorn T, Popat R, Wilson E. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium. *Fertil Steril.* 1983;39:292-7.
33. Yuzpe AA, Thurlow HJ, Ramzy I, Leyshon JI. Post coital contraception—a pilot study. *J Reprod Med.* 1974;13:53-8.
34. Taskin O, Brown RW, Young DC, Poindexter AN, Wiehle RD. High doses of oral contraceptives do not alter endometrial  $\alpha 1$  and  $\alpha v\beta 3$  integrins in the late implantation window. *Fertil Steril.* 1994;61:850-5.
35. Raymond EG, Lovely LP, Chen-Mok M, Seppälä M, Kurman RJ, Lessey BA. Effect of the Yuzpe regimen of emergency contraception on markers of endometrial receptivity. *Hum Reprod.* 2000;15:2351-5.
36. Glasier A. Emergency postcoital contraception. *N Engl J Med.* 1997;337:1058-64.
37. Ling WY, Wrixon W, Acorn T, Wilson E, Collins J. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. III. Effect of preovulatory administration following the luteinizing hormone surge on ovarian steroidogenesis. *Fertil Steril.* 1983;40:631-6.
38. Croxatto HB, Ortiz ME, Müller AL. Mechanisms of action of emergency contraception. *Steroids.* 2003;68:1095-8.
39. Trussell J, Raymond EG. Statistical evidence concerning the mechanism of action of the Yuzpe regimen of emergency contraception. *Obstet Gynecol.* 1999;93:872-6.
40. Trussell J, Ellertson C, von Hertzen H, Bigrigg A, Webb A, Evans M, Ferden S, Leadbetter C. Estimating the effectiveness of emergency contraceptive pills. *Contraception.* 2003;67:259-65.
41. *Statement on Contraceptive Methods.* Washington DC: American College of Obstetricians and Gynecologists, July 1998.

- <sup>42</sup> Díaz S, Cárdenas H, Brandeis A, Miranda P, Salvatierra AM, Croxatto HB. Relative contributions of anovulation and luteal phase defect to the reduced pregnancy rate of breastfeeding women. *Fertil Steril* 1992;**58**:498-503.
- <sup>43</sup> Lewis PR, Brown JB, Renfree MB, Short RV. The resumption of ovulation and menstruation in a well-nourished population of women breastfeeding for an extended period of time. *Fertil Steril* 1991;**55**:529-536.
- <sup>44</sup> Brown JB, Harrison P, Smith MA. A study of returning fertility after childbirth and during lactation by measurement of urinary oestrogen and pregnanediol excretion and cervical mucus production. *J Biosoc Science* 1985;**9**(Suppl):5-23.
- <sup>45</sup> Gray RH, Campbell OM, Apelo R, Eslami SS, Zacur H, Ramos RM, Gehret JC, Lobbok MH. Risk of ovulation during lactation. *Lancet* 1990;**335**:25-9.